Treatment of Helicobacter pylori infection in atrophic gastritis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
(Hp) is a major human pathogen causing chronic, progressive gastric mucosal damage and is linked to gastric atrophy and cancer. Hp-positive individuals constitute the major reservoir for transmission of infection. There is no ideal treatment for Hp. Hp infection is not cured by a single antibiotic, and sometimes, a combined treatment with three or more antibiotics is ineffective. Atrophic gastritis (AG) is a chronic disease whose main features are atrophy and/or intestinal metaplasia of the gastric glands, which arise from long-standing Hp infection. AG is reportedly linked to an increased risk for gastric cancer, particularly when extensive intestinal metaplasia is present. Active or past Hp infection may be detected by conventional methods in about two-thirds of AG patients. By immunoblotting of sera against Hp whole-cell protein lysates, a previous exposure to Hp infection is detected in all AG patients. According to guidelines, AG patients with Hp positivity should receive eradication treatment. The goals of treatment are as follows: (1) Cure of infection, resolution of inflammation and normalization of gastric functions; (2) possible reversal of atrophic and metaplastic changes of the gastric mucosa; and (3) prevention of gastric cancer. An ideal antibiotic regimen for Hp should achieve eradication rates of approximately 90%, and complex multidrug regimens are required to reach this goal. Amongst the factors associated with treatment failure are high bacterial load, high gastric acidity, Hp strain, smoking, low compliance, overweight, and increasing antibiotic resistance. AG, when involving the corporal mucosa, is linked to reduced gastric acid secretion. At a non-acidic intra-gastric pH, the efficacy of the common treatment regimens combining proton pump inhibitors with one or more antibiotics may not be the same as that observed in patients with Hp gastritis in an acid-producing stomach. Although the efficacy of these therapeutic regimens has been thoroughly tested in subjects with Hp infection, there is a paucity of evidence in the subgroup of patients with AG. Bismuth-based therapy may be an attractive treatment in the specific setting of AG, and specific studies on the efficacy of bismuth-based therapies are needed in patients with AG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kyoto global consensus report on Helicobacter pylori gastritis
Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., & Malfertheiner, P. (2015) · Gut · doi:10.1136/gutjnl-2015-309252 · Cited by 1,876
Systematic review: gastric cancer incidence in pernicious anaemia
Vannella, L., Lahner, E., Osborn, J., & Annibale, B. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12177 · Cited by 235
Self-citationThe interaction between smoking, alcohol and the gut microbiome
Capurso, G., & Lahner, E. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.10.006 · Cited by 182
Self-citationIncidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies
Adamu, M. A., Weck, M. N., Gao, L., & Brenner, H. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9482-0 · Cited by 140
Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis
VANNELLA, L., LAHNER, E., OSBORN, J., BORDI, C., MIGLIONE, M., DELLE FAVE, G., & ANNIBALE, B. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04268.x · Cited by 110
Self-citationA follow up model for patients with atrophic chronic gastritis and intestinal metaplasia
Dinis-Ribeiro, M., Lopes, C., da Costa-Pereira, A., Guilherme, M., Barbosa, J., Lomba-Viana, H., Silva, R., & Moreira-Dias, L. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.11270 · Cited by 109
Two‐thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection
Annibale, B., Negrini, R., Caruana, P., Lahner, E., Grossi, C., Bordi, C., & Fave, G. D. (2001) · Helicobacter · doi:10.1046/j.1083-4389.2001.00032.x · Cited by 107
Self-citationReversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
Vannella, L., Lahner, E., Bordi, C., Pilozzi, E., Di Giulio, E., Corleto, V. D., Osborn, J., Delle Fave, G., & Annibale, B. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.012 · Cited by 56
Self-citationAnnibale, B., Lahner, E., Santucci, A., Vaira, D., Pasquali, A., Severi, C., Mini, R., Figura, N., & Fave, G. D. (2007) · Helicobacter · doi:10.1111/j.1523-5378.2007.00467.x · Cited by 45
Self-citation
Cited by
Lahner, E., Zagari, R. M., Zullo, A., Di Sabatino, A., Meggio, A., Cesaro, P., Lenti, M. V., Annibale, B., & Corazza, G. R. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.016 · Cited by 187
Self-citationGastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164
A current clinical overview of atrophic gastritis
Annibale, B., Esposito, G., & Lahner, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1718491 · Cited by 84
“because of the presence of the impaired gastric acid secretion due to the atrophic damage of the corpus oxyntic glands [107].”
BackgroundSelf-citationLevothyroxine absorption test—results and follow up of patients from a single center
Subramaniam, K., Babu, T., Sreevalsan, K. C., & Mathew, S. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_188_21 · Cited by 4
Metadata
- Authors
- Lahner, E., Carabotti, M., & Annibale, B.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2018-06-14
- Volume
- 24
- Issue
- 22
- Pages
- 2373-2380
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2806892300
- Cited by
- 99
- References
- 9
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Helicobacter pylori infection in atrophic gastritis. https://app.cochat.ai/papers/10.3748/wjg.v24.i22.2373
- The paper
- Lahner, E., Carabotti, M., & Annibale, B. (2018). Treatment of Helicobacter pylori infection in atrophic gastritis. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v24.i22.2373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.